Home > Insider Trading > Filing (0001209191-19-004547)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1654151	Deciphera Pharmaceuticals Inc.	DCPH	Pharmaceutical Preparations (2834)	200299725

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1713712	Lee Daniel Flynn	C/O Deciphera Pharmaceuticals, Inc. 500 Totten Pond Road Waltham MA 02451	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-03-23	91,779	$0.00	91,779	No	5	G	Indirect	By Daniel L. Flynn Irrevocable Trust
Common Stock	Disposition	2018-03-23	91,779	$0.00	55,270	No	5	G	Indirect	By Biochenomix, LLC
Common Stock	Acquisiton	2019-01-16	152,629	$1.89	152,629	No	4	M	Direct
Common Stock	Disposition	2019-01-16	152,629	$26.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Indirect	By Daniel L. Flynn Irrevocable Trust
No	5	G	Indirect	By Biochenomix, LLC
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-01-16	152,629	$0.00	152,629	$1.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
472,678		2025-12-17	No	4	M	Direct

Footnotes

This transaction involved a transfer of shares to the Daniel L. Flynn Irrevocable Trust from Biochenomix, LLC. The Reporting Person's daughter is trustee of the trust and the Reporting Person's spouse is the sole lifetime beneficiary of the trust. The Reporting Person disclaims Section 16 beneficial ownership over all such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that the Reporting Person has beneficial ownership of such shares for Section 16 or for any other purposes.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.